Clinical trial
Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients…
NCT00074282 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00074282 |
|---|---|
| Title | Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL |
| Official title | Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previously Treated Relapsed or Refractory Patients With Chronic Lymphocytic Leukemia |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | rituximab, cyclophosphamide, pentostatin, Alemtuzumab |
| Enrollment | 102 |
| Start date | Apr 14, 2005 |
| Primary completion | Dec 9, 2017 |
| Completion | May 6, 2018 |
| First posted | Dec 11, 2003 |
| Last update posted | Jun 29, 2023 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: